Literature DB >> 17873891

Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas.

Zhi Rong Qian1, Toshiaki Sano, Katsuhiko Yoshimoto, Sylvia L Asa, Shozo Yamada, Noriko Mizusawa, Eiji Kudo.   

Abstract

The gene products of CDH13 and CDH1, H-cadherin and E-cadherin, respectively, play a key role in cell-cell adhesion. Inactivation of the cadherin-mediated cell adhesion system caused by aberrant methylation is a common finding in human cancers, indicating that the CDH13 and CDH1 function as tumor suppressor and invasion suppressor genes. In this study, we analyzed the expression of H-cadherin mRNA and E-cadherin protein in 5 normal pituitary tissues and 69 primary pituitary adenomas including all major types by quantitative real-time RT-PCR (qRT-PCR) and immunohistochemistry, respectively. Reduced expression of H-cadherin was detected in 54% (28/52) of pituitary tumors and was significantly associated with tumor aggressiveness (P<0.05). E-cadherin expression was lost in 30% (21 of 69) and significantly reduced in 32% (22 of 69) of tumors. E-cadherin expression was significantly lower in grade II, III, and IV than in grade I adenomas (P=0.015, P=0.029, and P=0.01, respectively). Using methylation-specific PCR (MSP), promoter hypermethylation of CDH13 and CDH1 was detected in 30 and 36% of 69 adenomas, respectively, but not in 5 normal pituitary tissues. Methylation of CDH13 was observed more frequently in invasive adenomas (42%) than in non-invasive adenomas (19%) (P<0.05) and methylation of CDH1 was more frequent in grade IV adenomas compared with grade I adenomas (P<0.05). Methylation of either CDH13 or CDH1 was identified in 35 cases (51%) and was more frequent in grade IV invasive adenomas than in grade I non-invasive adenomas (P<0.05 and P<0.05, respectively). Downregulation of expression was correlated with promoter hypermethylation in CDH13 and CDH1. In conclusion, the tumor-specific downregulation of expression and methylation of CDH13 and CDH1, alone or in combination, may be involved in the development and invasive growth of pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873891     DOI: 10.1038/modpathol.3800965

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  35 in total

1.  Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Authors:  Ying-Li Lin; Xiao-Qiang Liu; Wen-Ping Li; Guang Sun; Chun-Ting Zhang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

2.  Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion.

Authors:  Ye Gu; Xinyao Zhou; Fan Hu; Yong Yu; Tao Xie; Yuying Huang; Xinzhi Zhao; Xiaobiao Zhang
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

3.  A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype.

Authors:  Chao Ling; Matthew Pease; Lingling Shi; Vasu Punj; Mark S Shiroishi; Deborah Commins; Daniel J Weisenberger; Kai Wang; Gabriel Zada
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

4.  Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma.

Authors:  Lobna Alkebsi; Hiroshi Handa; Akihiko Yokohama; Takayuki Saitoh; Norifumi Tsukamoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2016-09-09       Impact factor: 2.967

5.  Different levels of various glucocorticoid-regulated genes in corticotroph adenomas.

Authors:  Johan Arild Evang; Jens Bollerslev; Olivera Casar-Borota; Tove Lekva; Jon Ramm-Pettersen; Jens Petter Berg
Journal:  Endocrine       Date:  2013-01-13       Impact factor: 3.633

Review 6.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

7.  Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters.

Authors:  Bo Zhai; He-Xin Yan; Shu-Qin Liu; Lei Chen; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

8.  Expression and clinical significance of p120 catenin mRNA and protein in pancreatic carcinoma.

Authors:  Yang Fei; Zhangjun Cheng; Shengli Liu; Xushun Liu; Zi Ge; Feng Wang; Guangquan Zong; Wei Wang
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

Review 9.  Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis.

Authors:  Maria Gueorguiev; Ashley B Grossman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 10.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.